Quantitative Flow Ratio to Predict Non-Target-Vessel Events Prior to Planned Staged PCI in ACS Patients

Background: The optimal timepoint of staged percutaneous coronary intervention (sPCI) among patients with acute coronary syndrome (ACS) and multivessel disease (MVD) remains a matter of debate. Quantitative Flow Ratio (QFR) is a novel non-invasive method to assess the hemodynamic significance of coronary stenoses. We aimed to investigate whether QFR could optimize the timing of sPCI of non-target-vessels (non-TV) among ACS patients with MVD. Methods: For this cohort study, ACS patients discharged from Bern University Hospital, Switzerland, were eligible if non-TV sPCI was scheduled within 6 months after index PCI. The primary endpoint was non-TV myocardial infarction (MI) and urgent unplanned non-TV PCI before planned sPCI. The association between lowest QFR per patient measured in non-TV (from index angiogram) and the primary endpoint was assessed using a multivariable adjusted Cox proportional hazards regression with QFR included as linear and penalized spline (non-linear) terms. Results: QFR was measured in 1093/1432 ACS patients scheduled to undergo non-TV sPCI. Median time to sPCI was 28 days. The primary endpoint occurred in 5% of the patients. In multivariable analysis (1018 patients), there was no independent association between non-TV QFR and the primary endpoint (HR 0.87, 95% CI 0.69-1.05 [per 0.1 increase], p=0.125; non-linear p=0.648). Conclusions: In ACS patients scheduled to undergo sPCI at a median of 4 weeks after index PCI, QFR did not emerge as independent predictor of non-TV events prior to planned sPCI. Thus, this study does not provide conceptual evidence, that QFR is helpful to optimize the timing of sPCI.

[1]  J. Escaned,et al.  Improved Nonculprit Stenosis Assessment in Patients With ST-Segment Elevation Myocardial Infarction Using Quantitative Flow Ratio. , 2023, JACC. Cardiovascular interventions.

[2]  E. Boersma,et al.  Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial , 2023, The Lancet.

[3]  Yan Lai,et al.  Angiographic quantitative flow ratio in acute coronary syndrome: beyond a tool to define ischemia-causing stenosis—a literature review , 2022, Cardiovascular diagnosis and therapy.

[4]  L. Räber,et al.  Effect of Timing of Staged Percutaneous Coronary Intervention on Clinical Outcomes in Patients With Acute Coronary Syndromes , 2021, Journal of the American Heart Association.

[5]  P. Serruys,et al.  Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial , 2021, The Lancet.

[6]  S. Bangalore,et al.  Prognostic value of fractional flow reserve using computed tomography for predicting major adverse cardiac events and mortality in kidney transplant candidates , 2021, European Heart Journal.

[7]  G. Chatellier,et al.  Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction. , 2021, The New England journal of medicine.

[8]  L. Räber,et al.  Quantitative Flow Ratio to Predict Nontarget Vessel–Related Events at 5 Years in Patients With ST‐Segment–Elevation Myocardial Infarction Undergoing Angiography‐Guided Revascularization , 2021, Journal of the American Heart Association.

[9]  Deepak L. Bhatt,et al.  2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2020, European heart journal.

[10]  F. Neumann,et al.  The Natural History of Nonculprit Lesions in STEMI: An FFR Substudy of the Compare-Acute Trial. , 2020, JACC. Cardiovascular interventions.

[11]  C. Macaya,et al.  Angiography-derived functional assessment of non-culprit coronary stenoses during primary percutaneous coronary intervention for ST-elevation myocardial infarction. , 2020, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[12]  Marco Valgimigli,et al.  2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. , 2019, European heart journal.

[13]  M. Keltai,et al.  Timing of Staged Nonculprit Artery Revascularization in Patients With ST-Segment Elevation Myocardial Infarction: COMPLETE Trial. , 2019, Journal of the American College of Cardiology.

[14]  Á. Avezum,et al.  Complete Revascularization with Multivessel PCI for Myocardial Infarction. , 2019, The New England journal of medicine.

[15]  Ajay K. Jain,et al.  Complete Versus Culprit-Only Lesion Intervention in Patients With Acute Coronary Syndromes. , 2018, Journal of the American College of Cardiology.

[16]  Jeroen J. Bax,et al.  Diagnostic performance of angiography-derived fractional flow reserve: a systematic review and Bayesian meta-analysis , 2018, European heart journal.

[17]  H. Bøtker,et al.  Diagnostic Performance of In‐Procedure Angiography‐Derived Quantitative Flow Reserve Compared to Pressure‐Derived Fractional Flow Reserve: The FAVOR II Europe‐Japan Study , 2018, Journal of the American Heart Association.

[18]  A. M. Leone,et al.  Quantitative Flow Ratio Identifies Nonculprit Coronary Lesions Requiring Revascularization in Patients With ST-Segment–Elevation Myocardial Infarction and Multivessel Disease , 2018, Circulation. Cardiovascular interventions.

[19]  F. Fedele,et al.  Single-Staged Compared With Multi-Staged PCI in Multivessel NSTEMI Patients: The SMILE Trial. , 2016, Journal of the American College of Cardiology.

[20]  L. Køber,et al.  Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial , 2015, The Lancet.

[21]  T. Jernberg,et al.  Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. , 2015, European heart journal.

[22]  H. Swanton,et al.  Randomized Trial of Complete Versus Lesion-Only Revascularization in Patients Undergoing Primary Percutaneous Coronary Intervention for STEMI and Multivessel Disease , 2015, Journal of the American College of Cardiology.

[23]  C. Berry,et al.  Randomized trial of preventive angioplasty in myocardial infarction. , 2013, The New England journal of medicine.

[24]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[25]  N. Pijls,et al.  The crux of maximum hyperemia: the last remaining barrier for routine use of fractional flow reserve. , 2011, JACC. Cardiovascular interventions.

[26]  Akiko Maehara,et al.  A prospective natural-history study of coronary atherosclerosis. , 2011, The New England journal of medicine.

[27]  U. Siebert,et al.  Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. , 2010, Journal of the American College of Cardiology.

[28]  P. Serruys,et al.  Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[29]  F. Loop,et al.  Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). , 1988, Circulation.

[30]  G. Thanassoulis,et al.  Fractional Flow Reserve–Guided Multivessel Angioplasty in Myocardial Infarction. , 2017, The New England journal of medicine.

[31]  J. Mehilli,et al.  [2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)]. , 2016, Giornale italiano di cardiologia.

[32]  K. Mahaffey,et al.  ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation , 2012 .